期刊
MOLECULAR INTERVENTIONS
卷 6, 期 3, 页码 162-169出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mi.6.3.7
关键词
-
资金
- NIDA NIH HHS [DA00254, T32 DA07267] Funding Source: Medline
- NIGMS NIH HHS [T32 GM07767] Funding Source: Medline
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [P01DA000254, P50DA000254, T32DA007267] Funding Source: NIH RePORTER
Activation of the delta-opioid receptor (DOR) system produces an interesting behavioral profile distinct from that of other opioids. Unlike mu- and kappa-opioid agonists, delta-opioid agonists alone have limited pain-relieving qualities as measured in morphine-sensitive antinociceptive assays. Recent evidence, however, suggests that the DOR system may play a role in regulating mood and emotional states. For example, DOR activation stimulates robust antidepressant-like effects in preclinical assays, suggesting that these compounds may have therapeutic potential for treating human depression. This review discusses the role of the DORs in depression and the antidepressant-like effects of delta-opioid agonists as well as their limitations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据